A carregar...

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years) who met DSM-IV-TR criteria for MDD and had screening a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Child Adolesc Psychopharmacol
Main Authors: Atkinson, Sarah, Lubaczewski, Shannon, Ramaker, Sara, England, Richard D., Wajsbrot, Dalia B., Abbas, Richat, Findling, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771531/
https://ncbi.nlm.nih.gov/pubmed/29185786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2017.0099
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!